Drug Pricing

Politics By Rachel Cohrs

Medicare plans to restrict access to controversial, pricey Alzheimer’s drug Aduhelm to patients in clinical trials

Politics By Rachel Cohrs

Becerra orders Medicare to reconsider premium hike following price drop for Biogen’s Aduhelm

Pharmalot By Rachel Cohrs and Ed Silverman

Biden administration poised to give pharmacies a major lobbying win

First Opinion By Reshma Ramachandran, Tianna Zhou and Joseph S. Ross

Out-of-pocket drug costs for Medicare beneficiaries need to be reined in

First Opinion By Fred D. Ledley

Why the big questions about drug prices are rarely asked: It’s hard to do

Pharmalot By Ed Silverman

Generic drug makers win a court round as judge temporarily blocks California pay-to-delay law

Pharmalot By Ed Silverman

Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug

Pharmalot By Ed Silverman

Centene agrees to pay $28 million to resolve another state probe into its pharmacy benefits business

Politics By Nicholas Florko

As Biden touts his effort to cap insulin prices, advocates push for an even more ambitious reform

First Opinion By Tahir Amin and Priti Krishtel

Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing

Pharmalot By Ed Silverman

Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals

Pharmalot By Ed Silverman

Socially responsible investor coalitions push greater access to medicines in shareholder proposals

D.C. Diagnosis By Nicholas Florko

What does the Build Back Better Act actually mean for the health care industry?

Politics By Rachel Cohrs

Democrats’ major drug pricing reforms clear a hurdle in the House

Pharmalot By Ed Silverman

Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass

Politics By Nicholas Florko

Moderate Democrats are still seeking changes to the party’s drug pricing package

Pharmalot By Ed Silverman

‘Can’t get much worse’: What a European rejection of an Alzheimer’s drug would mean for Biogen

Pharmalot By Ed Silverman

The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020

Pharmalot By Ed Silverman

Pfizer strikes a deal with the Medicines Patent Pool for generic versions of its Covid-19 pill in poor countries

Pharmalot By Ed Silverman

Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B

First Opinion By Peter Kolchinsky

Drug pricing bill’s unintended consequences will distort drug development

Politics By Erin Mershon, Rachel Cohrs and Lev Facher

STAT+ Conversation: Drug pricing drama

Exclusive By Rachel Cohrs

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Hospitals & Prescription cost -- backup still

Pharmalot By Ed Silverman

Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs

First Opinion By Dan Leonard

Most Read

Chilean health ministry is urged to issue a compulsory license for the Pfizer Covid pill

‘It’s almost negligible’: More top hospitals aren’t offering controversial Alzheimer’s drug Aduhelm

Drug makers ring in the new year with 5% price hikes on hundreds of medicines

HHS appeals rulings over drug discount program just as AbbVie is latest to cut discounts

Will the Biden administration use ‘march-in’ to protect prostate cancer patients from excessive drug prices?

3 pharma trends to watch in 2022

‘For good rather than evil’: Mark Cuban and an employer’s coalition to launch new PBMs to lower drug costs

The four senators who could make or break Democrats’ drug pricing ambitions

All Coverage

Medicare plans to restrict access to controversial, pricey Alzheimer’s drug Aduhelm to patients in clinical trials

Becerra orders Medicare to reconsider premium hike following price drop for Biogen’s Aduhelm

Biden administration poised to give pharmacies a major lobbying win

Out-of-pocket drug costs for Medicare beneficiaries need to be reined in

Why the big questions about drug prices are rarely asked: It’s hard to do

Generic drug makers win a court round as judge temporarily blocks California pay-to-delay law

Martin Shkreli’s former company pays $40 million for blocking competition for a life-saving drug

Centene agrees to pay $28 million to resolve another state probe into its pharmacy benefits business

As Biden touts his effort to cap insulin prices, advocates push for an even more ambitious reform

Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing

Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals

Socially responsible investor coalitions push greater access to medicines in shareholder proposals

What does the Build Back Better Act actually mean for the health care industry?

Democrats’ major drug pricing reforms clear a hurdle in the House

Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass

Moderate Democrats are still seeking changes to the party’s drug pricing package

‘Can’t get much worse’: What a European rejection of an Alzheimer’s drug would mean for Biogen

The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020

Pfizer strikes a deal with the Medicines Patent Pool for generic versions of its Covid-19 pill in poor countries

Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B

Drug pricing bill’s unintended consequences will distort drug development

STAT+ Conversation: Drug pricing drama

How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal

Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs

The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars